pravastatin has been researched along with Lung Neoplasms in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Chen, WM; Shia, BC; Wu, SY; Yu, YH | 1 |
| Aksoy, HN; Ceylan, C | 1 |
| Popat, S | 1 |
| Crosse, B; Cullen, M; Fife, KM; Hackshaw, A; Harden, S; Middleton, G; Muthukumar, D; Nash, S; Ngai, Y; Ottensmeier, CH; Schmid, P; Seckl, MJ; Taylor, P; Thompson, J | 1 |
| Brower, V | 1 |
| Ravnskov, U | 1 |
| Blanc, JF; Dugot-Senant, N; Laurendeau, I; Rosenbaum, J; Rullier, A; Taras, D; Vidaud, M | 1 |
1 trial(s) available for pravastatin and Lung Neoplasms
| Article | Year |
|---|---|
Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease-Free Survival; Double-Blind Method; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pravastatin; Response Evaluation Criteria in Solid Tumors; Small Cell Lung Carcinoma; Survival Rate | 2017 |
6 other study(ies) available for pravastatin and Lung Neoplasms
| Article | Year |
|---|---|
Statin Use During Concurrent Chemoradiotherapy With Improved Survival Outcomes in Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Nationwide Cohort Study.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Cohort Studies; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lung Neoplasms; Pravastatin; Propensity Score; Rosuvastatin Calcium | 2023 |
Comparison of the Effects of Statins on A549 Nonsmall-Cell Lung Cancer Cell Line Lipids Using Fourier Transform Infrared Spectroscopy: Rosuvastatin Stands Out.
Topics: A549 Cells; Atorvastatin; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipids; Lovastatin; Lung Neoplasms; Pravastatin; Rosuvastatin Calcium; Simvastatin; Spectroscopy, Fourier Transform Infrared | 2021 |
Do Statins Improve Survival in Small-Cell Lung Cancer?
Topics: Double-Blind Method; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lung Neoplasms; Pravastatin; Small Cell Lung Carcinoma | 2017 |
Pravastatin has no advantage in small-cell lung cancer.
Topics: Antineoplastic Agents; Clinical Decision-Making; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Humans; Lung Neoplasms; Patient Selection; Pravastatin; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Time Factors; Treatment Outcome | 2017 |
Re: The association between statins and cancer incidence in a veterans population.
Topics: Anticholesteremic Agents; Antineoplastic Agents; Bias; Colorectal Neoplasms; Confounding Factors, Epidemiologic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lung Neoplasms; Male; Neoplasms; Pravastatin; Prostatic Neoplasms; Simvastatin; United States; Veterans | 2008 |
Pravastatin reduces lung metastasis of rat hepatocellular carcinoma via a coordinated decrease of MMP expression and activity.
Topics: Animals; Enzyme Inhibitors; Gene Expression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms, Experimental; Lung Neoplasms; Male; Matrix Metalloproteinase 14; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Pravastatin; Rats; Rats, Inbred F344 | 2007 |